SCHEMBL2889328

SCHEMBL2889328

CCOC(=O)c1ncc2c(cc(-c3ccc(Cl)cc3)n2Cc2ccc3c(c2)OCO3)c1OC(=O)C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.44
MAPT P10636 4/20 0.44
LMNA P02545 3/20 0.44
HPGD P15428 2/20 0.44
CYP19A1 P11511 1/20 0.43
HSD17B10 Q99714 3/20 0.39
KDM4E B2RXH2 2/20 0.39
TP53 P04637 1/20 0.39
PDE1C Q14123 1/20 0.38
EDNRB P24530 4/20 0.38
EDNRA P25101 4/20 0.38
GAA P10253 2/20 0.38
ALOX15 P16050 2/20 0.38
TSHR P16473 2/20 0.38
ELANE P08246 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
SIRT2 Q8IXJ6 2/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2886872 0.87 SMN1; SMN2 (0.50) SMN1; SMN2MAPTLMNAHPGDCYP19A1
SCHEMBL2886803 0.86 CYP19A1 (0.43) SMN1; SMN2MAPTLMNAHPGDCYP19A1
SCHEMBL2887809 0.85 CYP19A1 (0.42) SMN1; SMN2MAPTLMNAHPGDCYP19A1
SCHEMBL2887960 0.79 SMN1; SMN2 (0.51) SMN1; SMN2MAPTLMNAHPGDCYP19A1
SCHEMBL2883552 0.76 LMNA (0.53) SMN1; SMN2MAPTLMNAHPGDCYP19A1
SCHEMBL2889255 0.76 SMN1; SMN2 (0.47) SMN1; SMN2MAPTLMNAHPGDCYP19A1
SCHEMBL2887137 0.74 SMN1; SMN2 (0.46) SMN1; SMN2MAPTLMNAHPGDCYP19A1
SCHEMBL2889332 0.74 CYP19A1 (0.37) CYP19A1TP53ELANE
SCHEMBL2889330 0.73 KDM4E (0.44) SMN1; SMN2MAPTLMNAHPGDCYP19A1
SCHEMBL2881020 0.73 EGLN1 (0.54) SMN1; SMN2MAPTHPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
EP-2016078-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2009-01-21 EP disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed
WO-2007115315-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 SMN1; SMN2 3919/4885MAPT 2965/4885LMNA 4255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.